Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EPS (Weighted Average and Diluted) (2020 - 2025)

Cytek Biosciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.34 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 585.71% year-over-year to -$0.34; the TTM value through Dec 2025 reached -$0.51, down 920.0%, while the annual FY2025 figure was -$0.52, 940.0% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.34 in Q4 2025 per CTKB's latest filing, down from -$0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.07 in Q4 2024 to a low of -$0.34 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.04, with a median of -$0.04 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 600.0% in 2023, then surged 120.0% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at $0.03 in 2022, then soared by 33.33% to $0.04 in 2023, then surged by 75.0% to $0.07 in 2024, then crashed by 585.71% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's EPS (Weighted Average and Diluted) are -$0.34 (Q4 2025), -$0.04 (Q3 2025), and -$0.04 (Q2 2025).